Spectrum Pharmaceuticals (NASDAQ:SPPI – Get Rating) had its price objective lowered by HC Wainwright from $12.00 to $9.00 in a report published on Tuesday, The Fly reports. HC Wainwright currently has a buy rating on the biotechnology company’s stock.
Several other equities analysts have also recently weighed in on SPPI. Cantor Fitzgerald reissued a neutral rating on shares of Spectrum Pharmaceuticals in a research note on Wednesday, June 8th. StockNews.com cut shares of Spectrum Pharmaceuticals from a hold rating to a sell rating in a research report on Sunday. Finally, JMP Securities reissued a buy rating and issued a $4.00 target price on shares of Spectrum Pharmaceuticals in a research report on Tuesday, June 7th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and three have issued a buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of Hold and an average price target of $5.67.
Spectrum Pharmaceuticals Stock Performance
Shares of NASDAQ:SPPI opened at $0.66 on Tuesday. The company has a debt-to-equity ratio of 0.15, a current ratio of 1.79 and a quick ratio of 1.79. The company has a market capitalization of $124.73 million, a price-to-earnings ratio of -0.91 and a beta of 1.86. The firm’s 50 day simple moving average is $1.08 and its 200 day simple moving average is $0.97. Spectrum Pharmaceuticals has a fifty-two week low of $0.60 and a fifty-two week high of $2.47.
Institutional Inflows and Outflows
Spectrum Pharmaceuticals Company Profile
Spectrum Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes oncology and hematology drug products. The company's products under development include Eflapegrastim, a novel long-acting granulocyte colony-stimulating factor for chemotherapy-induced neutropenia; Poziotinib, a novel irreversible tyrosine kinase inhibitor for non-small cell lung cancer tumors with various mutations; and Anti-CD20-IFNa, an antibody-interferon fusion molecule directed against CD20 that is in Phase I development for the treatment of patients with relapsed or refractory non-Hodgkin's lymphoma, including diffuse large B-cell lymphoma.
- Get a free copy of the StockNews.com research report on Spectrum Pharmaceuticals (SPPI)
- 3 Airline Stocks Stuck in a Holding Pattern
- Roku Stock is Down but Not Out
- If You’re Hungry for Value, Take a Bite on Ruth’s Hospitality Grp
- Is Ford Rolling To A Rebound After Its Q3 Warning
- Has AMD stock stock fallen too far?
Receive News & Ratings for Spectrum Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spectrum Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.